Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 132

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 132
---
 we have or may establish, or by any distributors or other commercial partners we have engaged or may engage to obtain any regulatory approvals required to market, sell, and use our tests in various countries; 41 •challenges predicting the market for our tests and services generally and tailoring our services to meet varying customer expectations in different countries and jurisdictions; •difficulties gaining market share in jurisdictions in which we do not have a strong physical presence or brand awareness; •complexities and difficulties obtaining protection for and enforcing our intellectual property rights; •difficulties in staffing and managing foreign operations and the increased travel, infrastructure and legal compliance costs associated with multiple international locations and subsidiaries; •complexities associated with managing multiple payor coverage and reimbursement regimes, government payors, or patient self -paysystems; •financial risks, such as longer payment cycles, difficulty collecting trade accounts receivable and the impact of local and regional financial conditions on demand and payment for our tests; •exposure to foreign currency exchange rate fluctuations, conversions of currencies, and the risk of repatriation of certain foreign currencies; •natural disasters, political and economic instability, including wars (e.g., the war in Ukraine), terrorism and political unrest, outbreak of disease, boycotts, and other business restrictions; and •regulatory and compliance risks related to applicable anti -briberylaws, including requirements to maintain accurate information and control over activities that may fall within the purview of these laws. Any of these factors could significantly harm our existing relationships with international customers or derail our international expansion plans, which would cause our revenue and results of operations to suffer. In addition, we are exposed to a number of additional risks and challenges related to our current operations in Argentina and our potential future operations in Mexico. These risks include, among others, difficulties predicting the market for genetic testing for a specific market; competitive factors in this market, including challenges securing market share; local differences in customer demands and preferences and regulatory requirements; and many of the other risks of doing business internationally that are discussed above. Although we believe our regional operations could result in expanded long -termopportunities to address the genetic testing market in Latin America, and eventually, the U.S., this belief could turn out to be wrong, and we may never realize these or any other benefits we anticipate from our international expansion. Moreover, any future market expansion we may seek to establish may never produce sufficient revenue for us to recover our capital and other investments, and we could become subject to liabilities based on our involvement in any